Almstead Neil Gregory 4

What Happened
Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics (PTCT), sold 3,989 shares in an open-market/private sale on March 5, 2026. The shares were sold at $63.38 per share for total proceeds of $252,823. This was a sale (disposition), which is typically routine; purchases generally carry more weight as a bullish signal.

Key Details

• Transaction date and price: 2026-03-05 — 3,989 shares sold at $63.38 each.
• Total value: $252,823 (proceeds from the sale).
• Filing date: Form 4 filed 2026-03-09 — filing appears timely (filed within required business-day window).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: Transaction executed pursuant to a written Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025 (per footnote F1).
• Transaction code: S (sale / disposition).

Context
The sale was made under a pre-established 10b5-1 plan, which means the trades were scheduled in advance and are generally considered routine rather than a contemporaneous signal about the insider’s view of the company. For retail investors, note that while insider buys can indicate confidence, sales under trading plans are commonly used for diversification or liquidity and don’t necessarily reflect negative views.